A Phase 2 interventional study of Imatinib tablets and Hydroxyurea capsules in Recurrent Glioblastoma Multiforme (GBM), sponsored by Novartis. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-16.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing imatinib in Glioblastoma — none open to participants now, none under way, none of them phase 3. imatinib · Glioblastoma.
Among the 10 studies testing imatinib in Glioblastoma, this one is the 2nd largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 5th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →None of the 10 studies testing imatinib in Glioblastoma is open now. The open studies under Glioblastoma, anywhere →
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1
First in 2001; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 65 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
22 studies in Glioblastoma by Novartis: none open now, 4 under way, none of them phase 3. Of 18 finished, 8 (44%) have results posted.
Among the 22 studies in Glioblastoma by Novartis, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 6 in phase 2, and was the 6th registered.
Novartis’s Glioblastoma studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing imatinib in Glioblastoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 22 in Glioblastoma:
This tab as a report to print or save as PDF → With an account.
This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with recurrent glioblastoma multiforme (brain tumors). This study also evaluated the duration of tumor response (as per MacDonald criteria), clinical benefit, progression-free survival rate at 6 and 12 months, and the survival rate at 12 and 24 months.
This ClinicalTrials.gov record includes the results from two studies (Novartis protocol IDs CSTI571H2201 and CSTI571H2202) which were conducted separately but reported together in a single clinical study report. Both studies were phase II, open-label, multicenter, single-arm studies that evaluated the efficacy of imatinib mesylate plus hydroxyurea in subjects with progressive glioblastoma multiforme. The studies were identical in design with two exceptions: Patients in study CSTI571H2201 received a dose of imatinib 600 mg once daily and were not allowed concomitant use of enzyme-inducing anticonvulsant drugs (EIACDs); patients in study CSTI571H2202 received a dose of imatinib 500 mg twice daily and were allowed concomitant use of EIACDs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who were not a minimum of 12 weeks from completion of conventional external beam radiotherapy unless:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.
Drug: Imatinib tablets · Drug: Hydroxyurea capsules
Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.
Drug: Imatinib tablets · Drug: Hydroxyurea capsules
Imatinib was supplied as 100 and 400 mg tablets by Novartis.
Also known as: Glivec®
Hydroxyurea was supplied locally as 500 mg capsules.
Percentage of Patients With an Objective Overall Response (OOR)
Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).
Time frame: Baseline to end of study (Month 24)
Duration of Objective Overall Response (OOR)
Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.
Time frame: Baseline to end of study (Month 24)
Percentage of Patients Who Had Clinical Benefit
Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.
Time frame: Baseline to end of study (Month 24)
Percentage of Patients With Progression-free Survival at Months 6 and 12
Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.
Time frame: Months 6 and 12
Percentage of Patients Surviving at Months 6, 12, and 24
Patients not known to have died were censored at the time of last survival follow-up.
Time frame: Months 6, 12, and 24
Number of Patients With at Least 1 Adverse Event
An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.
Time frame: Baseline to end of study (Month 24)
| Milestone | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|
| Started | 131 | 100 |
| Completed | 4 | 3 |
| Not completed | 127 | 97 |
| Withdrew: Disease progression | 95 | 73 |
| Withdrew: Death | 11 | 10 |
| Withdrew: Adverse event | 12 | 6 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Administrative problems | 2 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).
| Percentage of participants | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|---|
| Percentage of Patients With an Objective Overall Response (OOR) | 3.8 (1.3 to 8.7) | 3.0 (0.6 to 8.5) | 3.5 (1.5 to 6.7) |
Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.
| Weeks | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|---|
| Duration of Objective Overall Response (OOR) | 41.1 (32.1 to 53.6) | 32.1 (20.1 to NA) | 37.1 (32.1 to 53.6) |
Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.
| Percentage of participants | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|---|
| Percentage of Patients Who Had Clinical Benefit | 9.9 (5.4 to 16.4) | 6.0 (2.2 to 12.6) | 8.2 (5.0 to 12.5) |
Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.
| Percentage of participants | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|---|
| 6 Months | 11.2 (5.7 to 16.6) | 9.9 (3.8 to 15.9) | 10.6 (6.5 to 14.7) |
| 12 Months | 6.9 (2.4 to 11.3) | 3.3 (0.0 to 6.9) | 5.3 (2.3 to 8.3) |
Patients not known to have died were censored at the time of last survival follow-up.
| Percentage of participants | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|---|
| 6 Months | 49.2 (40.7 to 57.8) | 50.9 (40.9 to 61.0) | 50.0 (43.4 to 56.5) |
| 12 Months | 28.5 (20.7 to 36.2) | 31.3 (21.9 to 40.7) | 29.7 (23.7 to 35.7) |
| 24 Months | 10.7 (3.3 to 18.1) | 20.3 (11.8 to 28.9) | 13.9 (8.0 to 19.7) |
An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.
| Participants | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|---|
| Number of Patients With at Least 1 Adverse Event | 129 | 98 | 227 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib 600 mg + Hydroxyurea 1000 mg | — | 62/131 (47.3%) | 122/131 (93.1%) |
| Imatinib 1000 mg + Hydroxyurea 1000 mg | — | 53/99 (53.5%) | 95/99 (96%) |
| Event | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/131 | 12/99 |
| General physical health deteriorationGeneral disorders | 10/131 | 3/99 |
| PneumoniaInfections and infestations | 7/131 | 0/99 |
| VomitingGastrointestinal disorders | 2/131 | 5/99 |
| ConvulsionNervous system disorders | 6/131 | 5/99 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/131 | 5/99 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/131 | 2/99 |
| NauseaGastrointestinal disorders | 1/131 | 4/99 |
| HeadacheNervous system disorders | 4/131 | 4/99 |
| Intracranial pressure increasedNervous system disorders | 4/131 | 4/99 |
| Event | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg |
|---|---|---|
| NauseaGastrointestinal disorders | 49/131 | 37/99 |
| FatigueGeneral disorders | 40/131 | 37/99 |
| VomitingGastrointestinal disorders | 40/131 | 22/99 |
| HeadacheNervous system disorders | 33/131 | 20/99 |
| Oedema peripheralGeneral disorders | 31/131 | 24/99 |
| DiarrhoeaGastrointestinal disorders | 27/131 | 16/99 |
| ConstipationGastrointestinal disorders | 22/131 | 9/99 |
| DizzinessNervous system disorders | 13/131 | 15/99 |
| AnaemiaBlood and lymphatic system disorders | 19/131 | 10/99 |
| ThrombocytopeniaBlood and lymphatic system disorders | 19/131 | 10/99 |
| Age Continuous(years) | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | Total |
|---|---|---|---|
| Mean | 53.7 ± 11.9 | 52.8 ± 11.4 | 53.3 ± 11.7 |
| Sex: Female, Male(Participants) | Imatinib 600 mg + Hydroxyurea 1000 mg | Imatinib 1000 mg + Hydroxyurea 1000 mg | Total |
|---|---|---|---|
| Female | 52 | 35 | 87 |
| Male | 79 | 65 | 144 |
The record gives a start of Feb 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Imatinib · Hydroxyurea